Curium's strategic investment of over €32 million will establish a European production line for 177Lu-PSMA-I&T, a therapeutic agent for patients with metastatic castration-resistant prostate cancer ...
Berlin, Germany and Paris, France, March 01, 2021 (GLOBE NEWSWIRE) -- Eckert & Ziegler Radiopharma GmbH and Curium PET France have decided to reinforce their existing long term partnership by ...
Primary staging of patients with high-risk prostate cancer prior to initial curative therapy To localize recurrence of prostate cancer in patients with a suspected recurrence based on increasing serum ...
PARIS, June 01, 2026 (GLOBE NEWSWIRE) -- Curium, a global leader in nuclear medicine, today announced at the Choose France summit in Versailles, a major industrial investment program in France to the ...
PARIS, May 30, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, today announced that earlier this month patients in France received the first doses of PYLCLARI ® (INN: ...
ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness. Curium’s strategic investment of over €32 million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results